Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.

@article{Kumar2007AktcAMPresponsiveEB,
  title={Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by Nexrutine, a Phellodendron amurense bark extract.},
  author={Addanki P Kumar and Shylesh S Bhaskaran and Manonmani Ganapathy and Katherine E Crosby and Michael D. Davis and Peter V. Kochunov and John Schoolfield and I-Tien Yeh and Dean A. Troyer and R. P. Ghosh},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2007},
  volume={13 9},
  pages={2784-94}
}
PURPOSE Development of prostate cancer prevention strategies is an important priority to overcome high incidence, morbidity, and mortality. Recently, we showed that Nexrutine, an herbal extract, inhibits prostate cancer cell proliferation through modulation of Akt and cAMP-responsive element binding protein (CREB)-mediated signaling pathways. However, it is unknown if Nexrutine can be developed as a dietary supplement for the prevention of prostate cancer. In this study, we used the transgenic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 12 references

Phase II study of pomegranate juice for menwith risingprostate specific antigen following surgery or radiation for prostate cancer

  • AJ Pantuck, LeppertJT, N Zomorodian
  • Clin Cancer Res
  • 2006

Molecular genetics of prostate cancer

  • CA Shen, MM Shen
  • Genes Dev 2001;14:2410^34
  • 2001

Similar Papers

Loading similar papers…